Pharming Group Announces Presentations at 2025 ACAAI Annual Scientific Meeting

Pharming Group N.V. announced that 12 abstracts have been accepted for presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting. The presentations will showcase new data across the company's rare disease portfolio, including RUCONEST® for hereditary angioedema (HAE) and Joenja® for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS). Five posters will present new clinical, economic, and comparative data for RUCONEST®, while seven posters will highlight the real-world effectiveness of Joenja®, including additional results from the Phase III pediatric trial. The presentations aim to advance understanding and treatment options for these rare diseases.